Arvinas Shares Dive on Trial Results for Metastatic Breast Cancer Treatment
Arvinas shares dived 40% following results from a Phase 3 clinical trial evaluating vepdegestrant as a treatment for a type of metastatic breast cancer. Shares were trading around $10.35. The stock is down 61% over the last year.
MLive - GrandRapids/Muskegon/Kalamazoo on MSN2h
Pfizer sells park land to Portage for $1PORTAGE, MI — Portage plans to purchase land along Portage Creek for $1. Pfizer owned the vacant, 4.6-acre lot at 6510 Lovers ...
Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.
Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...
WASHINGTON, D.C. U.S. Senate Democratic Whip Dick Durbin (D-IL) sent letters to five telehealth companies that have held ...
Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...
Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...
An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback